SCHEDULE 13G/A: Vanguard Group Discloses 10.15% Stake in Neurocrine Biosciences

The Vanguard Group has filed an amended Schedule 13G, revealing a beneficial ownership of 10.15% in Neurocrine Biosciences Inc.'s common stock as of February 28, 2025.

Summary

• The Vanguard Group, an investment adviser, has filed an Amendment No. 9 to Schedule 13G regarding its beneficial ownership in Neurocrine Biosciences Inc.
• As of February 28, 2025, The Vanguard Group beneficially owns an aggregate of 10,129,687 shares of Neurocrine Biosciences Inc. Common Stock.
• This ownership represents 10.15% of the class of securities.
• The Vanguard Group holds sole voting power over 0 shares, shared voting power over 66,089 shares, sole dispositive power over 9,976,666 shares, and shared dispositive power over 153,021 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or prospects. It is a routine regulatory filing.

Future Outlook

This document, a Schedule 13G, is a beneficial ownership report and does not contain forward-looking statements or guidance from Neurocrine Biosciences Inc. or The Vanguard Group regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by The Vanguard Group)

Industry Context

This filing indicates a significant passive investment by a major asset manager, The Vanguard Group, in a biotechnology company, Neurocrine Biosciences Inc. Such large institutional holdings are common in the pharmaceutical and biotech sectors, reflecting investor confidence or inclusion in broad market indices.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by The Vanguard Group provides transparency regarding the ownership structure of Neurocrine Biosciences Inc., which can influence investor perception and trading activity.

Key Dates

Keywords

Neurocrine Biosciences, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Institutional Ownership